Results 81 to 90 of about 6,851 (174)

Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers.

Indian J Dermatol
Kenkare VL, Madke B, Choudhary A, Bose S.   +3 more
europepmc   +1 more source

A Cross Sectional and Longitudinal Assessment of Neuropsychiatric Symptoms and Brain Functional Connectivity in Patients With Mild Cognitive Impairment, Cerebrovascular Disease and Parkinson Disease. [PDF]

Int J Geriatr Psychiatry
Rashidi-Ranjbar N, Churchill NW, Black SE, Kumar S, Tartaglia MC, Freedman M, Lang A, Ramirez J, Saposnik G, McLaughlin PM, Symons S, Pollock BG, Rajji TK, Borrie M, Masellis M, Pasternak SH, Frank A, Seitz D, Ismail Z, Tang-Wai DF, Scott CJM, Dowlatshahi D, Hassan A, Munoz DG, Fornazzari L, Fischer CE, Schweizer TA.   +26 more
europepmc   +1 more source

The Role of Adipokines and Gene Polymorphisms in the Development of Obesity- Induced Depression. [PDF]

Curr Obes Rep
Ercan SN, Sanlier N.
europepmc   +1 more source

Lower incidence of diabetic retinopathy and worsening events after phentermine assisted weight loss across a large U.S. cohort. [PDF]

Eye (Lond)
Kumar M, Abbass NJ, Russell MW, Das N, Singh RP, Talcott KE.   +5 more
europepmc   +1 more source

Student Rights and Responsibilities [PDF]

, 2000
Nova Southeastern University
core   +1 more source

Tetrahydrocannabivarin is Not Tetrahydrocannabinol. [PDF]

Cannabis Cannabinoid Res
Haghdoost M, Peters EN, Roberts M, Bonn-Miller MO.   +3 more
europepmc   +1 more source

From Pharmacological Treatment to Neuromodulation: A Comprehensive Approach to Managing Gilles de la Tourette Syndrome. [PDF]

Int J Mol Sci
Monfrini E, Saleh C, Servello D, Jaszczuk P, Porta M.   +4 more
europepmc   +1 more source

Oral health effects of ecstasy (MDMA) and methamphetamine: a narrative review. [PDF]

Front Oral Health
Newell LR, Fouillen KJ, Orliaguet M, Kichenin J, Boisramé S.   +4 more
europepmc   +1 more source

Fatal familial insomnia: Reporting a case of the rare nightmare.

J Postgrad Med
Hogue E, Weinberg D, Palecek E.
europepmc   +1 more source

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases. [PDF]

Clin Trials
Girges C, Vijiaratnam N, King A, Auld G, McComish R, Chowdhury K, Ambler G, Maclagan K, Limousin P, Athauda D, Morris HR, Libri V, Foltynie T, Exenatide PD3 and MSA Trials Consortia.   +13 more
europepmc   +1 more source